Editas Medicine, Inc.
General ticker "EDIT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $179.1M (TTM average)
Editas Medicine, Inc. follows the US Stock Market performance with the rate: 42.4%.
Estimated limits based on current volatility of 5.5%: low 2.43$, high 2.71$
Factors to consider:
- Total employees count: 246 (-7.2%) as of 2024
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Insufficient funding, Commercialization delays, Intellectual property risks, Labor/talent shortage/retention, Security breaches
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.53$, 4.34$]
- 2026-12-31 to 2027-12-31 estimated range: [1.59$, 4.38$]
Short-term EDIT quotes
Long-term EDIT plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $78.12MM | $32.31MM | $40.52MM |
| Operating Expenses | $247.30MM | $283.47MM | $139.86MM |
| Operating Income | $-169.18MM | $-251.15MM | $-99.34MM |
| Non-Operating Income | $15.96MM | $14.06MM | $-60.72MM |
| Interest Expense | $0.00MM | $0.00MM | $6.17MM |
| R&D Expense | $177.65MM | $199.25MM | $40.52MM |
| Income(Loss) | $-153.22MM | $-237.09MM | $-160.06MM |
| Profit(Loss)* | $-153.22MM | $-237.09MM | $-160.06MM |
| Stockholders Equity | $349.10MM | $134.27MM | $27.29MM |
| Assets | $499.15MM | $341.59MM | $186.53MM |
| Operating Cash Flow | $-132.18MM | $-210.28MM | $-165.24MM |
| Capital expenditure | $4.72MM | $8.83MM | $0.61MM |
| Investing Cash Flow | $-3.73MM | $162.15MM | $138.67MM |
| Financing Cash Flow | $118.04MM | $56.03MM | $40.47MM |
| Earnings Per Share** | $-2.02 | $-2.88 | $-1.80 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.